Business Wire12h
Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine™ for Treating Metabolic Dysfunction-Associated Steatohepati…
Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...
Oncology Nurse Advisor1d
Older Age Predicts Worse Survival in Patients With HCC, Comorbidity Role Unclear
Researchers assessed the prognostic significance of older age and comorbidity burden on overall survival in patients with hepatocellular carcinoma.
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...
Monthly Prescribing Reference3d
Amezalpat Gets Fast Track Status for Hepatocellular Carcinoma
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
oncnursingnews1d
Amezalpat Receives FDA Fast Track Designation for Hepatocellular Carcinoma
Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.
Daily6d
Hepatocellular Carcinoma After Hepatitis C Cure: Study Emphasizes The Need for Long-Term Surveillance
China: A recent study published in the Annals of Hepatology has emphasized the influence of age on hepatocellular carcinoma ...